| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/04/2004 | WO2004017896A2 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| 03/04/2004 | WO2004017892A2 Drug eluting coatings for medical implants |
| 03/04/2004 | WO2004017810A2 Tumor specific oligosaccharide epitopes and use thereof |
| 03/04/2004 | WO2004017766A1 Novel nutraceutical compositions comprising biotin |
| 03/04/2004 | WO2004017736A1 Stable, low free formaldehyde, synergistic antimicrobial compositions of aldehyde donors and dehydroacetic acid |
| 03/04/2004 | WO2004017727A1 A method of treatment and prophylaxis |
| 03/04/2004 | WO2004009015A3 Combination therapy for the treatment of obesity |
| 03/04/2004 | WO2004007743A3 Use of cpg nucleic acids in prion-disease |
| 03/04/2004 | WO2004006906A3 Methods for the treatment of neoplasms |
| 03/04/2004 | WO2004005264A3 Imidazole compounds for the treatment of hepatitis c virus infections |
| 03/04/2004 | WO2004001059A3 Heterocyclic inhibitors of kinases |
| 03/04/2004 | WO2004000229A3 Treatment of human multiple myeloma by curcumin |
| 03/04/2004 | WO2004000043A3 Nutraceutic compositions and food supplements containing nadh |
| 03/04/2004 | WO2003106456A3 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity |
| 03/04/2004 | WO2003105901A3 Use of aromatase inhibitors for the treatment of growth failure |
| 03/04/2004 | WO2003105759A3 Pharmacologic inhibition of myc function |
| 03/04/2004 | WO2003101379A3 Pyranoindazoles and their use for the treatment of glaucoma |
| 03/04/2004 | WO2003097091A3 Glucan-based vaccines |
| 03/04/2004 | WO2003084544A3 Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| 03/04/2004 | WO2003082350A3 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| 03/04/2004 | WO2003082216A9 Neuroprotectant methods, compositions, and screening methods thereof |
| 03/04/2004 | WO2003077855A3 N3 alkylated benzimidazole derivatives as mek inhibitors |
| 03/04/2004 | WO2003075907A3 Small molecule entry inhibitors |
| 03/04/2004 | WO2003072043A3 A method of recuding anti-neoplastic agent induced side effects |
| 03/04/2004 | WO2003070229A3 Use of proteinase inhibitors in the treatment of autoimmune diseases |
| 03/04/2004 | WO2003068157A3 Kinase inhibitors and methods of use thereof |
| 03/04/2004 | WO2003065871A3 Methods and compositions for treating hematological disorders |
| 03/04/2004 | WO2003060082A3 Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 03/04/2004 | WO2003059276A3 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| 03/04/2004 | WO2003055980A3 Il-17 like molecules and uses thereof |
| 03/04/2004 | WO2003055442A3 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
| 03/04/2004 | WO2003054018A3 Anti-tirc7 antibodies in therapy of inflammatory diseases |
| 03/04/2004 | WO2003053222A3 Methods for treating conditions, disorders, or diseases involving cell death |
| 03/04/2004 | WO2003051365A3 Use of compounds of the benzamide family as immunosuppressant |
| 03/04/2004 | WO2003050311A3 Methods and compositions for diagnosing and treating hypotrichosis simplex |
| 03/04/2004 | WO2003050254A3 Novel chimeric tnf ligands |
| 03/04/2004 | WO2003050067A3 Vitamin d analogues |
| 03/04/2004 | WO2003049527A3 Mitotic kinesin inhibitors |
| 03/04/2004 | WO2003043640A3 Treatment of major depressive disorder using glucocorticoid receptor antagonists |
| 03/04/2004 | WO2003043574A3 Pharmaceutical compositions in particulate form |
| 03/04/2004 | WO2003042214A3 A2b adenosine receptor antagonists |
| 03/04/2004 | WO2003041687A3 Method for producing stable solutions of phenolic substances and resulting solutions |
| 03/04/2004 | WO2003041641A3 Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| 03/04/2004 | WO2003039466A8 Method of treating estrogen responsive breast cancer |
| 03/04/2004 | WO2003033025A3 Cyclodextrin complexes |
| 03/04/2004 | WO2003032916A3 Organosulfur inhibitors of tyrosine phosphatases |
| 03/04/2004 | WO2003032904A3 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 03/04/2004 | WO2003028714A3 Antioxidant combination composition and use thereof |
| 03/04/2004 | WO2003028642A9 Methods of inhibiting metastases |
| 03/04/2004 | WO2003026629A3 Modified release dosage forms |
| 03/04/2004 | WO2003026581A3 Pharmaceutical compositions and methods for treating cancer |
| 03/04/2004 | WO2003024928A3 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| 03/04/2004 | WO2003022844A3 Synthesis of epothilones intermediates thereto and analogues thereof |
| 03/04/2004 | WO2003020209A3 Processes for the production of alpha-difluoromethyl ornithine (dfmo) |
| 03/04/2004 | WO2003019198A3 Methods relating to treatment of atherosclerosis |
| 03/04/2004 | WO2003019196A3 Diagnosis and treatment of atherosclerosis |
| 03/04/2004 | WO2003015789A3 A pharmaceutical composition for dermal application |
| 03/04/2004 | WO2003015759A3 Treatment of hyperproliferative conditions of body surfaces |
| 03/04/2004 | WO2003014114A3 Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/04/2004 | WO2003011114A3 Methods for treating prostatitis |
| 03/04/2004 | WO2003002071A3 Individualized addiction cessation therapy |
| 03/04/2004 | WO2003000846A3 A novel g protein-coupled receptor, gave 3 |
| 03/04/2004 | WO2003000268A8 Use of na+ channel blockers and aspirin in manufacturing drugs for producing analgesia synergistically in mammals |
| 03/04/2004 | WO2003000173A3 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain |
| 03/04/2004 | WO2002098856A3 Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
| 03/04/2004 | WO2002096867A3 Inhibitors of protein kinase for the treatment of disease |
| 03/04/2004 | WO2002094178A3 Treatment of renal fibrosis |
| 03/04/2004 | WO2002085459A3 Antiangiogenic combination therapy for the treatment of cancer |
| 03/04/2004 | WO2002085248A3 Prostanoids augment ocular drug penetration |
| 03/04/2004 | WO2002083075A3 Akt and regulation of ra synovial fibroblast apoptosis |
| 03/04/2004 | WO2002082091A3 Method for identification of proteins from intracellular bacteria |
| 03/04/2004 | WO2002080855A3 Methods and compounds for decreasing cell toxicity or death |
| 03/04/2004 | WO2002078623A3 Uses of targeted oxidative therapeutic formulation in arteriosclerosis |
| 03/04/2004 | WO2002066000A3 Novel cosmetic slimming compositions containing boldine |
| 03/04/2004 | WO2002034277A8 Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara |
| 03/04/2004 | WO2002022134A8 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/04/2004 | WO2002020762A8 Tnf receptor-like molecules and uses thereof |
| 03/04/2004 | WO2002015938A8 Testosterone ester formulation for human use |
| 03/04/2004 | WO2002012502A9 Anti-tnf antibodies, compositions, methods and uses |
| 03/04/2004 | US20040044304 Local drug delivery using photosensitizer-mediated and electromagnetic radiation enhanced vascular permeability |
| 03/04/2004 | US20040044241 Novel succinate salt of O-desmethyl-venlafaxine |
| 03/04/2004 | US20040044227 From 1,3,8-octanetriol |
| 03/04/2004 | US20040044221 Anticancer ganets; drug resistance |
| 03/04/2004 | US20040044220 Antiinflammatory agents; anticancer agents; antiischemic agents |
| 03/04/2004 | US20040044215 Crystallization, filtration; neurokinins receptor antagonist |
| 03/04/2004 | US20040044213 Process for making substituted 8-arylquinolinium benzenesulfonate |
| 03/04/2004 | US20040044212 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors |
| 03/04/2004 | US20040044207 Aza-and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors |
| 03/04/2004 | US20040044204 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents |
| 03/04/2004 | US20040044201 Bone disorders; osteoporosis; oral diseases; antiarthritic agents |
| 03/04/2004 | US20040044086 Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism |
| 03/04/2004 | US20040044085 Oxidation resistance, vision defects, anticancer agents, sunscreen agents |
| 03/04/2004 | US20040044084 Anesthetics; anticonvulsants; antiepileptic agents |
| 03/04/2004 | US20040044083 Exo-S-mecamylamine formulation and use in treatment |
| 03/04/2004 | US20040044082 Adrenergic receptor antagonist |
| 03/04/2004 | US20040044081 Hypotensive agents; cardiovascular disorders; anticholesterol agents; antiarrhythmia agents |
| 03/04/2004 | US20040044080 Treatment of dyspareunia with topically administered nitroglycerin formulations |
| 03/04/2004 | US20040044078 Cosmetic and/or pharmaceutical emulsions |
| 03/04/2004 | US20040044077 Agents for inhibiting or restoring skin damage caused by drying and method for evaluating the same |
| 03/04/2004 | US20040044074 Pharmaceutical composition containing aminoacetonitril compounds and the use thereof for the preparation of a pharmaceutical composition for the treatment of endoparasitic pests in animals |